PMID- 9185663
OWN - NLM
STAT- MEDLINE
DCOM- 19970728
LR  - 20171116
IS  - 0360-4012 (Print)
IS  - 0360-4012 (Linking)
VI  - 48
IP  - 5
DP  - 1997 Jun 1
TI  - Treatment of rat hemiparkinson model with xenogeneic neural transplantation: 
      tolerance induction by anti-T-cell antibodies.
PG  - 385-96
AB  - To obtain basic knowledge for the application of xenogeneic neural 
      transplantation to patients with Parkinson's disease, the rejection process of 
      xenogeneic neural grafts in rats was examined and a therapy to control it was 
      developed. Tissues including the ventral mesencephalon were taken from mouse 
      embryos and transplanted into the right lateral ventricle of mature male rats. 
      Transplanted xenografts were usually rejected by day 15. To prevent the graft 
      rejection, host rats were treated with anti-T-cell receptor alphabeta (anti-TCR 
      alphabeta) or anti-CD2 monoclonal antibody (mAb) or by a combination of the two. 
      Anti-TCR alphabeta (1 mg/kg) and anti-CD2 (7 mg/kg) mAb were administered for 3 
      consecutive days (day -2, -1, and 0 of transplantation). Although the 
      administration of mAb against either CD2 or TCR alphabeta did not induce 
      tolerance, the combination therapy with anti-CD2 and anti-TCR alphabeta mAb 
      produced graft survival for more than 100 days. The tolerance induced by this 
      combined antibody therapy is antigen specific because rats with long-term 
      surviving neural xenograft accepted a second neural graft from the same donor 
      strain C3H/He mouse, but not from a third-party strain BALB/c mouse, without 
      additional treatment. In addition, T cells isolated from these rats did not 
      respond to cultured C3H/He brain cells, but did respond vigorously to BALB/c 
      brain cells in mixed lymphocyte reaction. More importantly, the finding that 
      xenograft transplantation with the proper treatment reduced the rotation rate of 
      6-OHDA-lesioned rats confirmed that surviving grafts functioned properly. The 
      results of the present study suggest that xenogeneic neural transplantation in 
      combination with T-cell-targeted immunotherapy is an effective approach for 
      treatment of Parkinson's disease.
FAU - Okura, Y
AU  - Okura Y
AD  - Department of Neurosurgery, Brain Research Institute, Niigata University, Japan.
FAU - Tanaka, R
AU  - Tanaka R
FAU - Ono, K
AU  - Ono K
FAU - Yoshida, S
AU  - Yoshida S
FAU - Tanuma, N
AU  - Tanuma N
FAU - Matsumoto, Y
AU  - Matsumoto Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Neurosci Res
JT  - Journal of neuroscience research
JID - 7600111
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (CD2 Antigens)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - EC 1.14.16.2 (Tyrosine 3-Monooxygenase)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*pharmacology
MH  - Brain Tissue Transplantation/*immunology
MH  - CD2 Antigens/immunology
MH  - Cerebral Ventricles/surgery
MH  - Graft Rejection/immunology
MH  - Graft Survival/immunology
MH  - Immune Tolerance/immunology
MH  - Immunohistochemistry
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C3H
MH  - Neurons/enzymology/immunology/transplantation
MH  - Parkinson Disease, Secondary/*surgery
MH  - Rats
MH  - Rats, Inbred F344
MH  - Receptors, Antigen, T-Cell/*immunology
MH  - Transplantation, Heterologous/*immunology
MH  - Tyrosine 3-Monooxygenase/analysis
EDAT- 1997/06/01 00:00
MHDA- 2000/06/20 09:00
CRDT- 1997/06/01 00:00
PHST- 1997/06/01 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1997/06/01 00:00 [entrez]
AID - 10.1002/(SICI)1097-4547(19970601)48:5<385::AID-JNR1>3.0.CO;2-A [pii]
PST - ppublish
SO  - J Neurosci Res. 1997 Jun 1;48(5):385-96.